A new research has revealed that an injection of a new experimental drug might be able to reduce heart attacks risks by decreasing cholesterol levels up to 75 per cent when combined with statin.
The findings showed that the drug evolocumab played a crucial role in lowering "bad" cholesterol levels, which is the main cause of maximum heart risks when given with the usual dose of statin, the Daily Express reported.
When the injection of drug is given, every two weeks or monthly, it blocks the substance which obstructs the liver's ability to eliminate cholesterol from the blood.
Julie Ward of the British Heart Foundation said that although the treatment is proving its worth, other factors like quite smoking, eating healthy and moderate exercising also play a vital role in curbing the health risks.
However, the report notified that further comprehensive research on the drug is still required for security and to determine the long term results.
The study results were published in Jama, the Journal of the American Medical Association.